A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System
ID Number 13-1226Principal Investigator(s)
Lewis R. Silverman
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to determine the tolerability and effectiveness of an oral formulation of experimental drug called Rigosertib in treating your condition and to find the best regimen of Rigosertib that can be given safely. An experimental drug is not approved by the United States Food and Drug Administration (FDA) for use except in research studies.
Although the mechanism of action of Rigosertib is not fully known, it is thought to kill cancer cells by two different actions: it stops the tumor cells from dividing and growing, and blocks the proteins involved in cell division causing cells to die. Early information about the potential beneficial effects of this oral drug in patients with MDS is encouraging. A few patients were able achieve transfusion independence.
Recruiting Patients: Yes